Use of Tachosil® for Lymph Sealing During Surgery
Launched by TAKEDA · Aug 8, 2013
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The aim of this non-interventional study (NIS) was to collect further knowledge on the routine use of TachoSil ® in lymph node surgery where its sealing property helps to reduce the rate of postoperative complications, especially of seroma formation. Some data are already available from gynecology, urology and thoracic surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stationary patients undergoing lymph node resection.
- Exclusion Criteria:
- • Contraindications, such as hypersensitivity to the active pharmaceutical ingredient or to another ingredient.
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greifswald, , Germany
Patients applied
Trial Officials
Medical Director
Study Director
Takeda Pharma Vertrieb GmbH & Co. KG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials